Barry M J, Williford W O, Chang Y, Machi M, Jones K M, Walker-Corkery E, Lepor H
Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, USA.
J Urol. 1995 Nov;154(5):1770-4. doi: 10.1016/s0022-5347(01)66780-6.
We assessed the relationship between changes in scores for the American Urological Association (AUA) symptom index and benign prostatic hyperplasia (BPH) impact index with patient global ratings of improvement in a large Veterans Affairs trial comparing different pharmacological therapies for BPH.
The primary analyses compared absolute score changes from baseline with global ratings of improvement at 13 weeks for 1,218 men.
Subjects who rated themselves as being slightly improved had a mean decrease in AUA symptom index and BPH impact index scores of 3.1 and 0.4 points, respectively. However, the baseline scores strongly influenced this relationship.
These data provide guidance for investigators using the AUA symptom index and BPH impact index as outcome measures.
在一项比较不同药物治疗良性前列腺增生(BPH)的大型退伍军人事务部试验中,我们评估了美国泌尿外科学会(AUA)症状指数和BPH影响指数的得分变化与患者总体改善评分之间的关系。
主要分析比较了1218名男性从基线开始的绝对得分变化与13周时的总体改善评分。
将自己评为稍有改善的受试者,其AUA症状指数和BPH影响指数得分平均分别下降3.1分和0.4分。然而,基线得分对这种关系有很大影响。
这些数据为使用AUA症状指数和BPH影响指数作为结局指标的研究人员提供了指导。